An interventional study of Breakfast in Type 2 Diabetes, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by University of Michigan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan — 5 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Michigan.
Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, this one is the 9th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2023, is one of 31 with no phase, and was the 32nd registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →5 of the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan are open now, in 2 countries. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 14–18 · Healthy volunteers
University of Michigan · Sites in United States
Ages 30–85
University of Michigan · Sites in Guatemala
Ages 18+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 48 across the 36 interventional studies, 133 across the 2 observational. Of the 31 that completed or were terminated, 10 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by University of Michigan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007404University of MichiganUnderstanding Metabolism and Inflammation Risks for Diabetes in Adolescents | 2026-12 |
| NCT04442451University of MichiganMechanisms of Fatigability With Diabetes | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, very low-carbohydrate breakfast-focused program in 120 adults with type 2 diabetes. The investigators measured acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.
More than 15% of U.S. adults with type 2 diabetes have poorly controlled blood glucose, here defined as a glycated hemoglobin (HbA1c) level of 7.0% or higher. These adults have an elevated health risk of a variety of outcomes, including amputation and mortality from cardiovascular disease and from all causes. Nutrition- focused interventions can be effective for improving glycemic control, reducing anti-hyperglycemic medications, and reducing body weight, all of which are critical outcomes for adults with type 2 diabetes. However, typical nutrition-focused interventions can be burdensome, often requiring complex instructions and a complete overhaul of one's diet. Additionally, adults with poorly controlled type 2 diabetes are more likely to have low literacy levels, which can be a barrier for adherence to complex interventions. Therefore, an effective intervention for adults with poorly controlled diabetes who may have lower health literacy levels is necessary to reduce both HbA1c levels and anti-hyperglycemic medications. Carbohydrate intake has the strongest impact on post-prandial glycemia of any dietary factor, and a very low-carbohydrate diet-due to its ability to improve glycemic control-is now recommended by the American Diabetes Association (ADA) for the treatment of type 2 diabetes. The investigators hypothesized that some of the benefits of a very low-carbohydrate diet may be available to individuals who change only their breakfasts to be very low-carbohydrate, rather than modifying their entire diet.
Thus, the investigators conducted an acceptability, feasibility, preliminary effectiveness trial of a 4-month, online, small- steps, low-literacy, very low-carbohydrate breakfast-focused program in 120 adults with poorly controlled type 2 diabetes. The investigators measured acceptability and feasibility, plus critical efficacy outcomes, such as changes in HbA1c, anti-hyperglycemic medications, glycemic variability, body weight, blood pressure, and lipids.
The investigators also tested whether factors such as sex, health literacy level, and baseline insulin resistance significantly moderate the impact of the intervention on change in HbA1c and change in anti-hyperglycemic medications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Materials encouraged eating a very low-carbohydrate breakfast (or first meal of the day), with no more than about 5-10 non-fiber (net) grams of carbohydrates each.
Behavioral: Breakfast
Participants were provided recipes and information to support this dietary change.
Intervention Satisfaction
A 1-item measure about intervention satisfaction. We asked participants, "How would you rate your overall satisfaction with the program?" The item was rated from 1 = very dissatisfied to 6 = very satisfied, with higher scores reflecting greater satisfaction.
Time frame: At 4 months
Assessment of Program Feasibility
For feasibility, the percentage of completed sessions out of 16 possible sessions was calculated for each participant, and the mean percentage across participants was reported.
Time frame: At Month 4
Weekly Dietary Adherence
A 1-item measure about dietary adherence. We asked participants to reflect on the past week and rate whether they ate a low-carbohydrate breakfast. The item was rated from 1 = not at all to 7 = very much so, with higher scores reflecting greater adherence. Dietary adherence was collected weekly over the 4-month intervention. Average adherence across the intervention was reported.
Time frame: Weekly over 4 months
Change in PROMIS Sleep Disturbance T-score
The 4-item PROMIS sleep disturbance subscale measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting more severe sleep problems. To assess the effect of dietary change on sleep disturbance, the change in PROMIS sleep disturbance T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Pain Interference T-score
The 4-item PROMIS subscale for pain interference measures the extent to which patients experience problems with pain interference over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater pain interference. To assess the effects of dietary changes on pain, the change in PROMIS pain interference T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Anxiety T-score
The 4-item PROMIS subscale for anxiety measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on anxiety, the change in PROMIS anxiety T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Depression T-score
The 4-item PROMIS subscale for depression measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on depression, the change in PROMIS depression T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Fatigue T-score
The 4-item PROMIS subscale for fatigue measures the extent to which patients experience problems with fatigue over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater fatigue. To assess the effects of dietary changes on fatigue, the change in PROMIS fatigue T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Physical Function T-score
The 4-item PROMIS subscale for physical function measures the extent to which patients experience problems with physical function over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better physical function. To assess the effects of dietary changes on physical function, the change in PROMIS physical function T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Social Roles T-score
The 4-item PROMIS subscale for social roles measures the extent to which patients experience problems with their social roles over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better social roles. To assess the effects of dietary changes on social roles, the change in PROMIS social roles T-scores from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in PROMIS Pain Intensity
The 1-item PROMIS subscale for pain intensity measures average pain intensity over the past 7 days using a 10-point Likert scale, with higher scores reflecting greater pain. To assess the effects of dietary changes on pain intensity, the change in PROMIS pain intensity score from baseline to 4 months was evaluated.
Time frame: Baseline, 4 months
Change in HbA1c
HbA1c is the proportion of hemoglobin in the blood that has glucose attached to it relative to total hemoglobin. It reflects average blood glucose levels over approximately the previous 2-3 months. To assess the effect of dietary change on HbA1c, the change in HbA1c from baseline to 4 months were evaluated. A negative change indicates an improvement in HbA1c from baseline.
Time frame: Baseline, 4 months
Change in Anti-hyperglycemic Medications
The Medication Effect Score (MES) quantifies the overall intensity of antiglycemic therapy based on potency and dosages of medications (Alexopoulos et al., 2021), with higher scores indicating greater medication intensity. It is interpreted as the reduction in HbA1c attributable to the medication regime. For each diabetes medication, the percentage of the maximum recommended daily dose is multiplied by an adjustment factor reflecting its expected hemoglobin A1c-lowering potency; these values are summed to yield the total MES. Scores range from 0 upward (no fixed maximum), with lower scores reflecting lower medication intensity. The change in MES from baseline to 4 months was evaluated, with negative values indicating a reduction in medication intensity.
Time frame: Baseline, 4 months
| Milestone | Very Low-carbohydrate Breakfast |
|---|---|
| Started | 119 |
| Completed | 115 |
| Not completed | 4 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Death | 1 |
A 1-item measure about intervention satisfaction. We asked participants, "How would you rate your overall satisfaction with the program?" The item was rated from 1 = very dissatisfied to 6 = very satisfied, with higher scores reflecting greater satisfaction.
| score on a scale | Very Low-carbohydrate Breakfast |
|---|---|
| Intervention Satisfaction | 5.44 ± 0.91 |
For feasibility, the percentage of completed sessions out of 16 possible sessions was calculated for each participant, and the mean percentage across participants was reported.
| percentage of sessions completed | Very Low-carbohydrate Breakfast |
|---|---|
| Assessment of Program Feasibility | 90.20 ± 17.59 |
A 1-item measure about dietary adherence. We asked participants to reflect on the past week and rate whether they ate a low-carbohydrate breakfast. The item was rated from 1 = not at all to 7 = very much so, with higher scores reflecting greater adherence. Dietary adherence was collected weekly over the 4-month intervention. Average adherence across the intervention was reported.
| score on a scale | Very Low-carbohydrate Breakfast |
|---|---|
| Weekly Dietary Adherence | 6.3 ± 1.1 |
The 4-item PROMIS sleep disturbance subscale measures the extent to which patients experience problems with sleep over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting more severe sleep problems. To assess the effect of dietary change on sleep disturbance, the change in PROMIS sleep disturbance T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Sleep Disturbance T-score | -0.2 (-1.6 to 1.2) |
The 4-item PROMIS subscale for pain interference measures the extent to which patients experience problems with pain interference over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater pain interference. To assess the effects of dietary changes on pain, the change in PROMIS pain interference T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Pain Interference T-score | -0.0 (-1.4 to 1.3) |
The 4-item PROMIS subscale for anxiety measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on anxiety, the change in PROMIS anxiety T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Anxiety T-score | -0.7 (-2.0 to 0.6) |
The 4-item PROMIS subscale for depression measures the extent to which patients experience depressive symptoms over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater depression. To assess the effects of dietary changes on depression, the change in PROMIS depression T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Depression T-score | -0.9 (-2.0 to 0.2) |
The 4-item PROMIS subscale for fatigue measures the extent to which patients experience problems with fatigue over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting greater fatigue. To assess the effects of dietary changes on fatigue, the change in PROMIS fatigue T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Fatigue T-score | -0.8 (-2.2 to 0.6) |
The 4-item PROMIS subscale for physical function measures the extent to which patients experience problems with physical function over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better physical function. To assess the effects of dietary changes on physical function, the change in PROMIS physical function T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Physical Function T-score | -0.4 (-1.3 to 0.5) |
The 4-item PROMIS subscale for social roles measures the extent to which patients experience problems with their social roles over the past 7 days using a 5-point Likert scale. The subscale is measured using T-scores (mean 50, SD 10), with higher scores reflecting better social roles. To assess the effects of dietary changes on social roles, the change in PROMIS social roles T-scores from baseline to 4 months was evaluated.
| T-score | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Social Roles T-score | 0.8 (-0.4 to 1.9) |
The 1-item PROMIS subscale for pain intensity measures average pain intensity over the past 7 days using a 10-point Likert scale, with higher scores reflecting greater pain. To assess the effects of dietary changes on pain intensity, the change in PROMIS pain intensity score from baseline to 4 months was evaluated.
| units on a scale | Very Low-carbohydrate Breakfast |
|---|---|
| Change in PROMIS Pain Intensity | 0.4 (0.0 to 0.8) |
HbA1c is the proportion of hemoglobin in the blood that has glucose attached to it relative to total hemoglobin. It reflects average blood glucose levels over approximately the previous 2-3 months. To assess the effect of dietary change on HbA1c, the change in HbA1c from baseline to 4 months were evaluated. A negative change indicates an improvement in HbA1c from baseline.
| % of hemoglobin with glucose (HbA1c) | Very Low-carbohydrate Breakfast |
|---|---|
| Change in HbA1c | -0.4 (-0.6 to -0.2) |
The Medication Effect Score (MES) quantifies the overall intensity of antiglycemic therapy based on potency and dosages of medications (Alexopoulos et al., 2021), with higher scores indicating greater medication intensity. It is interpreted as the reduction in HbA1c attributable to the medication regime. For each diabetes medication, the percentage of the maximum recommended daily dose is multiplied by an adjustment factor reflecting its expected hemoglobin A1c-lowering potency; these values are summed to yield the total MES. Scores range from 0 upward (no fixed maximum), with lower scores reflecting lower medication intensity. The change in MES from baseline to 4 months was evaluated, with negative values indicating a reduction in medication intensity.
| MES units | Very Low-carbohydrate Breakfast |
|---|---|
| Change in Anti-hyperglycemic Medications | -0.2 (-0.4 to -0.1) |
Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Very Low-carbohydrate Breakfast | 1/119 (0.8%) | 4/119 (3.4%) | 15/119 (12.6%) |
| Event | Very Low-carbohydrate Breakfast |
|---|---|
| EncephalitisInfections and infestations | 1/119 |
| Myocardial infarctionCardiac disorders | 1/119 |
| Pericardial effusionCardiac disorders | 1/119 |
| Colon cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/119 |
| Thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/119 |
| Event | Very Low-carbohydrate Breakfast |
|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 15/119 |
| Age, Continuous(years) | Very Low-carbohydrate Breakfast |
|---|---|
| Mean | 61.1 ± 11.1 |
| Sex/Gender, Customized(participants) | Very Low-carbohydrate Breakfast |
|---|---|
| Male | 44 |
| Female | 73 |
| Other | 2 |
| Ethnicity (NIH/OMB)(Participants) | Very Low-carbohydrate Breakfast |
|---|---|
| Hispanic or Latino | 9 |
| Not Hispanic or Latino | 109 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(participants) | Very Low-carbohydrate Breakfast |
|---|---|
| American Indian or Alaskan Native | 2 |
| Asian | 4 |
| Black or African American | 18 |
| Native Hawaiian or other Pacific Islander | 0 |
| White | 89 |
| More than one race | 4 |
| Other | 2 |
| Region of Enrollment(Participants) | Very Low-carbohydrate Breakfast |
|---|---|
| United States | 119 |
| PROMIS Sleep Disturbance T-score(T-score) | Very Low-carbohydrate Breakfast |
|---|---|
| Mean | 50.5 ± 7.8 |
| PROMIS Pain Interference T-score(T-score) | Very Low-carbohydrate Breakfast |
|---|---|
| Mean | 50.4 ± 8.8 |
| PROMIS Anxiety T-score(T-score) | Very Low-carbohydrate Breakfast |
|---|---|
| Mean | 50.3 ± 9.3 |
7 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Oct 2025, 26 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 26 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.